Biologically effective dose and overall survival in stereotactic body radiotherapy for lung tumors
- PDF / 333,145 Bytes
- 4 Pages / 595 x 842 pts (A4) Page_size
- 67 Downloads / 208 Views
memo https://doi.org/10.1007/s12254-020-00617-w
Biologically effective dose and overall survival in stereotactic body radiotherapy for lung tumors Osamu Tanaka · Norihiko Funaguchi · Sayaka Toyoshi · Takuya Taniguchi · Kousei Ono · Chiyoko Makita · Masayuki Matsuo
Received: 16 February 2020 / Accepted: 5 May 2020 © Springer-Verlag GmbH Austria, part of Springer Nature 2020
Summary Stereotactic body radiotherapy (SBRT) delivers precise concentric radiation to a tumor. It is well established that local control depends on the biologically effective dose (BED) delivered, with BED10 of ≥100 as a significant predictor of local control. The aim of this study was to evaluate factors associated with overall survival (OS) in inoperable lung cancer cases treated with SBRT. From 2013 to 2016, 22 patients with inoperable lung cancer treated with SBRT who could be followed up until their time of death were retrospectively enrolled. Data on sex, age, dose (Gray), number of fractions, BED (α/β = 10), pathology, tumor location, performance status, and background lung disease were collected. The median total dose at the isocenter was 50 Gy, and median BED was 120 Gy. OS was compared in groups with BED of ≥120 Gy (“high-BED”; n = 15) and BED of 6 Gy/fraction delivered over up to five fractions. A relatively small tumor requires treatment with between one and four dose fractions. SBRT has unique radiobiological characteristics and can result in dramatic tumor responses. The aim of this study was to evaluate factors associated with overall survival (OS) in inoperable lung cancer cases treated with SBRT.
National Clinical Trial number: UMIN000034389 O. Tanaka, M.D () · T. Taniguchi, M.P. · K. Ono, M.P. Department of Radiation Oncology, Asahi University Hospital, 3–23 Hashimoto-cho. Gifu city, Gifu 500-8523, Japan [email protected] N. Funaguchi, M.D. · S. Toyoshi, M.D. Department of Respiratory Medicine, Asahi University Hospital, 3–23 Hashimoto-cho. Gifu city, Gifu 500-8523, Japan C. Makita, M.D. · M. Matsuo, M.D. Department of Radiology, Gifu University Hospital, 1–1 Yanagido, Gifu city, Gifu 501-1194, Japan
K
Materials and methods From 2013 to 2016, 32 patients underwent SBRT for primary lung tumors at the authors’ hospital. Of these, 22 could be followed up until their time of death; these patients were retrospectively enrolled in this study and data from their electronic medical records were retrospectively analyzed. The study was approved by the Institutional Review Board of Asahi University Hospital and was registered with the National Critical Trial Register (number UMIN000034389). The requirement for informed consent was waived due to
Stereotactic body radiotherapy for lung tumor
original report
Table 1 Patient characteristics and univariate analysis of factors potentially related to overall survival
Factor
Median or number
SD (range)
P
Sex: male/female
10/12
–
0.33
Age (years)
77
8.8 (56–86)
0.21
Dose (Gy)
50
12.7 (15–60)
0.09
Number of fractions
6
2.8 (4–15)
Data Loading...
